US Stock MarketDetailed Quotes

PPBT Purple Biotech

Watchlist

2.690
-0.120-4.27%

Close Mar 26 16:00 ET

2.690
0.0000.00%

Post 20:01 ET

7.12MMarket Cap-0.54P/E (TTM)

Purple Biotech Stock Forum

Stock_Drift

Mar 21 23:40

Low Floats. 11:38am 3/21/25

$PMGC Holdings (ELAB.US)$ $Synergy CHC (SNYR.US)$ $Purple Biotech (PPBT.US)$ $Oblong (OBLG.US)$ $Star Equity (STRR.US)$ $Mangoceuticals (MGRX.US)$ $STAK Inc. (STAK.US)$ $LakeShore Biopharma (LSB.US)$ $Kadestone Capital Corp (KDSX.CA)$ $JBDI Holdings (JBDI.US)$ $Pacific Mercantile Bancorp (PNBK.US)$ $Comstock Holding (CHCI.US)$ $VivoPower (VVPR.US)$ $TEN Holdings (XHLD.US)$ $Transcode Therapeutics (RNAZ.US)$

Teddy123

Mar 10 20:59

Purple Biotech Reports Fourth Quarter and Full-Year 2024 Financial Results

$Purple Biotech (PPBT.US)$
Purple Biotech Reports Fourth Quarter and Full-Year 2024 Financial Results

Teddy123

Mar 5 20:20

Purple Biotech Granted New U.S. Patent for NT219 in Combination with EGFR Antibody Therapy, Enhancing Global IP Protection in Major Markets

$Purple Biotech (PPBT.US)$
Can Purple Biotech's Newly Patented Cancer Drug Combination Tackle Treatment Resistance?

Jaguar8

Mar 5 20:01

NEWS

$Purple Biotech (PPBT.US)$
Purple Biotech Granted New U.S. Patent for NT219 in Combination with EGFR Antibody Therapy, Enhancing Global IP Protection in Major Markets
Wednesday, 5th March at 7:00 am
NT219 in combination with EGFR antibody cetuximab (Erbitux) is currently entering a Phase 2 study for head and neck cancer
REHOVOT, Israel, March 05, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-...

Teddy123

Feb 18 20:25

Purple Biotech Advances NT219 into Phase 2 Head and Neck Cancer Trial

$Purple Biotech (PPBT.US)$
Revolutionary Cancer Drug NT219 Enters Phase 2 Trial Targeting $5B Market Opportunity

Jaguar8

Feb 18 20:01

NEWS

$Purple Biotech (PPBT.US)$
Purple Biotech Advances NT219 into Phase 2 Head and Neck Cancer Trial
Tuesday, 18th February at 7:00 am
NT219, a novel agent designed to overcome tumor resistance to drug therapy, will be evaluated in combination with the standard-of-care head and neck cancer drugs pembrolizumab (Keytruda) or cetuximab (Erbitux)
The study is conducted in collaboration with the University of Colorado Anschutz Medical Campus and is led by Dr. Antonio Jimeno, Professor and Director of ...

103404493

Jan 22 20:24

$Edible Garden (EDBL.US)$

Share Your Profit/Loss

Jaguar8

Dec 5, 2024 20:13

NEWS

$Purple Biotech (PPBT.US)$
Purple Biotech Announces Closing of $2.8 Million Registered Direct Offering of American Depositary Shares
Thursday, 5th December at 7:13 am
REHOVOT, Israel, Dec. 05, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that overcome tumor immune evasion and drug resistance, today announced the closing of its previously announced registered direct offering o...